Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andy Smith

Latest From Andy Smith

Stock Watch: How To Avoid Blockbuster Loss Of Exclusivity Bringing Your Company Down

What is the difference between companies with franchises that rise and then fall into obscurity, and those that keep on rising even after loss of exclusivity?

Stock Watch Companies

Stock Watch: Defeat Is The Mother Of Reinvention

Companies that are successful do not need to change their name, therapeutic area or product focus.

Stock Watch Business Strategies

Stock Watch: Orphan Drug Profitability Under Threat

The difficulty of finding and retaining patients with orphan diseases translates into higher marketing costs and adds to other restrictions that limit the attractiveness of some orphan drugs. Will the IRA exacerbate matters?

Stock Watch Rare Diseases

Stock Watch: Pfizer Gets Back To Business As Usual

Sales Of Pfizer’s pandemic products decline as other vaccines are scheduled for a second-half launch but the road back to 2022’s all-time high in annual revenues will not be easy.

Stock Watch Sales & Earnings

Stock Watch: Queasiness After The Humira Banquet

The second week of first-quarter earnings featured AbbVie’s announcement and a harsh stock price reaction. There were also far-reaching implications behind the results.

Stock Watch Biosimilars

Stock Watch: Novartis Earnings Get Interesting Boost

A number of facets from last quarter’s earnings season carried over to Novartis’s first-quarter report, including pipeline attrition and the dependence of sales growth on a single product. While new, still minor products are hoped eventually to buffer its patent expiries, help from another corner has emerged.

Stock Watch Sales & Earnings
See All
UsernamePublicRestriction

Register